The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

The FDA has determined that the nationwide shortage of semaglutide injection, used for both diabetes and weight loss, is resolved after more than two years of limited availability due to high demand.

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

Demand GLP-1 Medications as Prescription Drug Market Grows SCHAUMBURG, IL, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Giftify, Inc. (NASDAQ:GIFT) (the "Company"), the owner and operator of CardCash.com and ...

CardCash.com to Offer Cost-Effective Solutions for High-Demand GLP-1 Medications as Prescription Drug Market Grows SCHAUMBURG, IL / ACCESS Newswire / February 20, 2025 / Giftify, Inc. (NASDAQ:GIFT) (t ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...